Literature DB >> 18644188

Radiation quality-dependent bystander effects elicited by targeted radionuclides.

Marie Boyd1, Annette Sorensen, Anthony G McCluskey, Robert J Mairs.   

Abstract

The efficacy of radiotherapy may be partly dependent on indirect effects, which can sterilise malignant cells that are not directly irradiated. However, little is known of the influence of these effects in targeted radionuclide treatment of cancer. We determined bystander responses generated by the uptake of radioiodinated iododeoxyuridine ([*I]IUdR) and radiohaloanalogues of meta-iodobenzylguanidine ([*I]MIBG) by noradrenaline transporter (NAT) gene-transfected tumour cells. NAT specifically accumulates MIBG. Multicellular spheroids that consisted of 5% of NAT-expressing cells, capable of the active uptake of radiopharmaceutical, were sterilised by treatment with 20 kBqmL(-1) of the alpha-emitter meta-[211At]astatobenzylguanidine ([211At]MABG). Similarly, in nude mice, retardation of the growth of tumour xenografts containing 5% NAT-positivity was observed after treatment with [131I]MIBG. To determine the effect of subcellular localisation of radiolabelled drugs, we compared the bystander effects resulting from the intracellular concentration of [131I]MIBG and [131I]IUdR (low linear energy transfer (LET) beta-emitters) as well as [123I]MIBG and [123I]IUdR (high LET Auger electron emitters). [*I]IUdR is incorporated in DNA whereas [*I]MIBG accumulates in extranuclear sites. Cells exposed to media from [131I]MIBG- or [131I]IUdR-treated cells demonstrated a dose-response relationship with respect to clonogenic cell death. In contrast, cells receiving media from cultures treated with [123I]MIBG or [123I]IUdR exhibited dose-dependent toxicity at low dose but elimination of cytotoxicity with increasing radiation dose (i.e. U-shaped survival curves). Therefore radionuclides emitting high LET radiation may elicit toxic or protective effects on neighbouring untargeted cells at low and high dose respectively. It is concluded that radiopharmaceutical-induced bystander effects may depend on LET of the decay particles but are independent of site of intracellular concentration of radionuclide.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644188     DOI: 10.1211/jpp.60.8.0002

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  11 in total

1.  Molecular and cellular radiobiological effects of Auger emitting radionuclides.

Authors:  Amin I Kassis
Journal:  Radiat Prot Dosimetry       Date:  2010-11-24       Impact factor: 0.972

Review 2.  Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2011-10

3.  Bystander effect in tumor cells produced by Iodine-125 labeled human lymphocytes.

Authors:  Omar Mamlouk; Pichumani Balagurumoorthy; Ketai Wang; S James Adelstein; Amin I Kassis
Journal:  Int J Radiat Biol       Date:  2012-07-09       Impact factor: 2.694

4.  Induction of lethal bystander effects in human breast cancer cell cultures by DNA-incorporated Iodine-125 depends on phenotype.

Authors:  John M Akudugu; Edouard I Azzam; Roger W Howell
Journal:  Int J Radiat Biol       Date:  2012-05-16       Impact factor: 2.694

5.  Radiation-induced bystander effect in non-irradiated glioblastoma spheroid cells.

Authors:  Fahime Faqihi; Ali Neshastehriz; Shokouhozaman Soleymanifard; Robabeh Shabani; Nazila Eivazzadeh
Journal:  J Radiat Res       Date:  2015-07-09       Impact factor: 2.724

Review 6.  Introduction to radiobiology of targeted radionuclide therapy.

Authors:  Jean-Pierre Pouget; Catherine Lozza; Emmanuel Deshayes; Vincent Boudousq; Isabelle Navarro-Teulon
Journal:  Front Med (Lausanne)       Date:  2015-03-17

Review 7.  Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.

Authors:  Yana Dekempeneer; Marleen Keyaerts; Ahmet Krasniqi; Janik Puttemans; Serge Muyldermans; Tony Lahoutte; Matthias D'huyvetter; Nick Devoogdt
Journal:  Expert Opin Biol Ther       Date:  2016-05-19       Impact factor: 4.388

Review 8.  Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.

Authors:  Dana Haddad
Journal:  Front Oncol       Date:  2017-05-23       Impact factor: 6.244

9.  What is the Role of the Bystander Response in Radionuclide Therapies?

Authors:  Darren Brady; Joe M O'Sullivan; Kevin M Prise
Journal:  Front Oncol       Date:  2013-08-19       Impact factor: 6.244

Review 10.  Molecular imaging of oncolytic viral therapy.

Authors:  Dana Haddad; Yuman Fong
Journal:  Mol Ther Oncolytics       Date:  2015-02-04       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.